Journal article
Teclistamab in Relapsed or Refractory Multiple Myeloma
Abstract
To the Editor: Moreau and colleagues (August 11 issue)1 found that, in patients with relapsed or refractory myeloma, treatment with teclistamab, a T-cell–redirecting bispecific antibody that target...
Authors
Hindié E
Journal
New England Journal of Medicine, Vol. 387, No. 18, pp. 1721–1723
Publisher
Massachusetts Medical Society
Publication Date
November 3, 2022
DOI
10.1056/nejmc2211969
ISSN
0028-4793